Abstract
Pemphigus is a group of severe autoimmune diseases characterised by painful skin and mucous membrane blisters. Identification and management of pemphigus comorbidities are vital for reducing morbidity and mortality. The mainstay treatment remains corticosteroid therapy. However it has recently been supplemented by the anti-CD20 antibody Rituximab in moderate and severe conditions. Despite quick tapering of corticosteroids Rituximab promotes full remission off medication in 90 of patients allowing for a significant corticosteroid-sparing effect and a halved number of corticosteroid-related side events. The cases presented here gives a brief overview on pemphigus and its therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
